Quick Facts

• Therapeutic Domain: Bacterial Infections
• Key Applications: Addresses bacterial infections of the lower and upper respiratory tract, skin, and urinary tract.
• Specific Conditions: Approved for use in acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and early Lyme disease.

---

What Acrocef (Cefuroxime) Treats: Main Uses and Benefits

Cefuroxime is a prescription antibacterial agent utilized to manage various mild-to-moderate infections caused by susceptible organisms. Its therapeutic role is to support the resolution of established bacterial illness by affecting the growth of the microbes involved.

This medication is indicated for conditions including bacterial infections of the respiratory system, such as acute bacterial maxillary sinusitis, and acute exacerbations of chronic bronchitis. It also has an established role in addressing uncomplicated urinary tract infections and certain skin and soft-structure infections.

Additionally, Cefuroxime is an accepted therapy for early-stage Lyme disease (erythema migrans) in adults and pediatric patients aged 13 and older. Healthcare professionals rely on official guidance to determine appropriate use for each individual condition and patient demographic.

Appropriate use of antibacterial agents helps in managing the disease process and is a standard component of care for these specific conditions. Its primary function is to target and diminish the presence of susceptible bacterial strains responsible for the infection, assisting the body's natural defense mechanisms.

Eligibility Map: Who Can and Cannot Use Acrocef (Cefuroxime)

The eligibility to use Cefuroxime is governed by strict population-based rules defined in official government labeling (FDA, EMA, etc.).

Category	Eligibility Rule (Official Wording)
Populations for whom use is contraindicated	Patients with known severe hypersensitivity to Cefuroxime, any cephalosporin antibiotic, or any other beta-lactam antibacterial agent (e.g., penicillin) [Source 1.2, 1.7].
Populations for whom use is not recommended	Infants under 3 months of age (safety and effectiveness have not been established) [Source 2.5, 2.7]. Use in pregnancy or lactation is conditional, requiring assessment to ensure benefit outweighs risk [Source 3.1].
Condition-specific eligibility rules	Use requires caution and monitoring in patients with a history of colitis or severe gastrointestinal disease [Source 1.4, 3.2]. Dosage must be reduced in patients with markedly impaired renal function ( creatinine clearance < 30 mL/min) [Source 1.2].
Age-related eligibility rules	Adults and pediatric patients 13 years and older are eligible for most tablet indications [Source 2.5]. Use in children begins generally at 3 months of age for oral suspension [Source 2.7].

---

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use Cefuroxime by establishing non-negotiable contraindications based on allergic history and setting firm age thresholds for when use is deemed safe and effective. Eligibility for adults is primarily constrained by organ function, requiring mandatory adjustment for severe renal impairment, and specific comorbidity cautions for conditions like a history of colitis. These rules delineate the specific population boundaries for the drug's use, without providing clinical advice.

The official interaction profile of cefuroxime is defined by its effects on drug exposure and risks associated with specific co-administered agents, according to government regulatory documentation.

Pharmacokinetic and Exposure Modification

Interacting Agent	Official Effect and Restriction
Probenecid	Co-administration is not recommended; it inhibits renal tubular secretion, thereby increasing and prolonging cefuroxime plasma concentrations.
Gastric Acidity Reducers	Drugs like antacids or H2-receptor antagonists decrease the bioavailability of the oral form (cefuroxime axetil). Simultaneous use should be avoided.

Pharmacodynamic Risks and Interferences

• Potent Diuretics / Nephrotoxic Drugs: Concurrent use with agents such as furosemide or aminoglycosides increases the potential risk of nephrotoxicity. Monitoring of renal function is specifically noted for the elderly and patients with pre-existing renal impairment.
• Oral Contraceptives: Cefuroxime may reduce the efficacy of combined oral contraceptives due to interference with intestinal flora, which can affect estrogen reabsorption.
• Bacteriostatic Agents: Co-administration with bacteriostatic drugs, such as tetracyclines or chloramphenicol, may interfere with cefuroxime's bactericidal action.
• Gastrointestinal Inhibitors: Medicinal products that inhibit peristalsis are contraindicated if antibiotic-associated diarrhea is present.
• Diagnostic Tests: Cefuroxime use can lead to interference with certain laboratory assays, specifically causing a false-positive result for glucose in urine with copper reduction tests and a false-positive Coombs test, which may affect blood cross-matching procedures.

The Covalent Inhibition of Bacterial Cell Wall Assembly

Cefuroxime's primary mechanism is the covalent inhibition of bacterial Penicillin-Binding Proteins (PBPs), a group of enzymes essential for synthesizing the rigid peptidoglycan layer. This action stops the final cross-linking step of the bacterial cell wall synthesis pathway, leading to the structural failure and subsequent death of the susceptible microbial population.

---

Mechanism-Driven Lysis and Bactericidal Effect

The structural instability caused by PBP inhibition triggers a destructive mechanistic cascade that leads to bacterial cell lysis. This sequence involves the activation of bacterial autolytic enzymes, which, combined with osmotic pressure, causes the cell to burst. This destructive sequence results in the molecule's bactericidal effect profile.

---

Functional Scope and Mechanistic Constraints

The mechanism's action is permitted in the Central Nervous System (CNS) due to the molecule's ability to cross the blood-brain barrier when inflammation is present. However, the mechanism is constrained by bacterial defenses, particularly the enzymatic hydrolysis of the drug by certain beta-Lactamases, which renders Cefuroxime inactive before it can reach its target.

How to Use Acrocef (Cefuroxime)

Cefuroxime administration is strictly defined by the form and route, following official guidelines.

Administration Routes and Frequency

Administration Route	Typical Adult Dosing Frequency	Key Dosing Information
Oral (Tablets/Suspension)	Twice Daily (every 12 hours)	The standard dose range is 250 mg to 500 mg per dose for most infections.
Parenteral (IV/IM)	Every 8 or 12 hours	Dosing ranges from 750 mg to 1.5 g per dose, with higher frequencies for severe infections.

Contextual Administration Instructions

Oral Cefuroxime axetil suspension must be taken with food to ensure maximum absorption of the medicine. While tablets may be taken with or without food, intake with food is generally associated with increased absorption. To avoid altering the intended drug delivery, film-coated tablets must be swallowed whole and should not be crushed, broken, or chewed.

Treatment duration typically ranges from 5 to 10 days for most conditions. However, specific infections, such as early Lyme disease, require a longer course of up to 20 days.

Special Population and Handling Rules

For patients with impaired renal function, the dosage must be reduced based on the patient's creatinine clearance to prevent drug accumulation. For the injectable form (Cefuroxime sodium), the powder must be reconstituted and diluted according to preparation guidelines before it can be safely administered intravenously or intramuscularly.

Research Evidence / Overview of Studies for Acrocef (Cefuroxime)

This overview summarizes the types of clinical studies and research findings that describe the investigation of Cefuroxime, focusing only on the structure of the evidence and what has been observed in various study settings.

---

Evidence Base for Acute Exacerbations of Chronic Bronchitis

Research explored the use of Cefuroxime in conditions associated with acute or disruptive episodes, such as when symptoms of chronic bronchitis worsen suddenly. These studies were designed as controlled trials, often including other standard antibiotic treatments for comparison. Researchers monitored outcomes capturing phases of heightened symptom activity, using scores to track respiratory symptoms and examining patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to changes measured during the study period, often describing patterns observed across the different comparison groups. Research highlights changes measured during the study period related to the evolution of acute symptoms. Data regarding the optimal treatment duration is still emerging, with research exploring the efficacy of shorter courses compared to traditional, longer courses.

---

Evidence Base for Acute Bacterial Sinusitis

Studies were often comparative trials assessing short-term or episodic symptom patterns in patients with a clinical diagnosis of acute sinusitis. Researchers monitored both clinical outcomes, such as symptom changes or evolution, and, in some cases, radiologic or imaging response. The populations studied generally included adults and pediatric patients (typically aged 13 and older).

Studies report how symptoms evolved in the observed populations, with findings describing patterns of clinical cure across various trials. However, findings were mixed across different meta-analyses regarding the overall certainty of the evidence. A clearer understanding of the added clinical effect over supportive care for less severe cases is an area where research is ongoing.

---

Long-Term Research and Evidence Gaps

There is limited information for long-term outcomes regarding the risk of recurrence or subsequent complications beyond the follow-up periods of the initial trials, which generally lasted between 1 and 12 months. Evidence highlights what is known—such as the short-term outcomes measured during acute episodes—and what is still uncertain, such as the optimal regimen for managing treatment failure or recurrence. The findings reflect group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the study groups.

Key Studies & References Infections of the Lower Respiratory Tract: Therapeutic Guidelines

Common questions about Acrocef (Cefuroxime) (FAQ)

---

Q: What infections does Cefuroxime treat?

Official regulatory documents indicate that Cefuroxime is used to treat a variety of bacterial infections. These commonly include infections of the upper and lower respiratory tract, such as pharyngitis, tonsillitis, and acute bacterial sinusitis. It is also indicated for certain uncomplicated infections of the skin, urinary tract, and for treating early Lyme disease.

---

Q: Is it safe to take Cefuroxime with birth control pills?

Official product information notes that Cefuroxime may reduce the effectiveness of combined oral contraceptives. This effect is thought to occur due to the antibiotic interfering with the normal bacteria in the gut. The drug label advises that patients should discuss this potential interaction with a healthcare provider.

---

Q: Can Cefuroxime be used in pregnant or breastfeeding women?

Regulatory information states that use in pregnancy is typically only advised if the drug is clearly needed, as comprehensive studies on pregnant women are not available. Cefuroxime is also known to pass into human milk in small amounts. Official labeling states that a healthcare provider should assess the potential benefits against the risks before use during pregnancy or lactation.

---

Q: Do I need to refrigerate the Cefuroxime oral suspension?

Yes, the official patient information confirms that the prepared oral suspension must be stored in the refrigerator after it is mixed. Regulatory instructions state that the prepared suspension should not be frozen. Any remaining portion of the mixture must be discarded after 10 days, even if there is still medicine left.

---

Q: What should I do if I miss a dose of Cefuroxime?

Official patient information generally instructs that a missed dose should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory guidance suggests skipping the missed dose and continuing with the regular schedule. The labeling specifically notes that double doses should not be taken.

---

Q: What should I do if I think I've taken too much Cefuroxime (overdose)?

Official labeling notes that taking too much of a cephalosporin antibiotic, like Cefuroxime, can lead to signs of cerebral irritation, which may cause symptoms like seizures or encephalopathy. Regulatory documents indicate that in the event of a suspected overdose, a patient should seek immediate medical assistance.

---

Q: What are common brand names for Cefuroxime?

Cefuroxime is the international non-proprietary name for the active drug substance. It is available under various prescription brand names globally. In the United States, common brand names have historically included Ceftin for the oral form and Zinacef for the injectable form.

Storage and Disposal Requirements

Storage conditions for Cefuroxime are strictly defined by regulatory labeling and depend on the specific formulation. The unopened powder for injection must be stored below 25°C and protected from light in its original outer carton. The oral tablets must be kept at room temperature and away from excess heat and moisture, with the lid tightly closed.

Once prepared, the oral suspension must be stored in the refrigerator and must be discarded after 10 days. Reconstituted intravenous solutions maintain stability for 24 to 48 hours depending on temperature. All forms of Cefuroxime must be kept out of the reach and sight of children.

Any unused or expired product must be disposed of in accordance with local pharmaceutical waste requirements as mandated by official labeling.